A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

NCT03991559 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: Manganese Chloride
DRUG: Anti-PD-1 antibody
COMBINATION_PRODUCT: Systemic therapy

Sponsor

Chinese PLA General Hospital